Home › Products › Gene function › Viral transduction › Lentivirus › Premade lentiviral particles › Tet-On 3G transactivator

Lentivirus

Need help?

Contact Sales

Tet-On 3G transactivator lentiviral particles

Premade lentivirus to express the Tet-On 3G transactivator

Highly concentrated and purified lentivirus for delivery of the Tet-On 3G transactivator to target cells. Any gene of interest (GOI) under the control of a TRE3G promoter (P_TRE3G) can be tightly controlled by the presence and absence of doxycycline (Dox) in the culture medium. Learn more about Tet-On 3G inducible gene expression.

Cat. #

Product

Size

License

Quantity

Details

0055VCT

rLV.EF1.Tet3G-9

1 x 20 uL

USD $714.00

License Statement

ID Number
42	Use of the Tetracycline controllable expression systems (the "Tet Technology") is covered by a series of patents including U.S. Patent # 8383364, # 9181556 , European patents EP # 1954811, #2352833 and corresponding patent claims outside these regions which are proprietary to TET Systems GmbH & Co. KG. Academic research institutions are granted an automatic license with the purchase of this product to use the Tet Technology only for internal, academic research purposes, which license specifically excludes the right to sell, or otherwise transfer, the Tet Technology or its component parts to third parties. Notwithstanding the above, academic and not-for profit research institutions whose research using the Tet Technology is sponsored by for profit organizations, which shall receive ownership to any data and results stemming from the sponsored research, shall need a commercial license agreement from TET Systems in order to use the Tet Technology. In accepting this license, all users acknowledge that the Tet Technology is experimental in nature. TET Systems GmbH & Co. KG makes no warranties, express or implied or of any kind, and hereby disclaims any warranties, representations, or guarantees of any kind as to the Tet Technology, patents, or products. All others are invited to request a license from TET Systems GmbH & Co. KG prior to purchasing these reagents or using them for any purpose. Takara Bio USA, Inc. is required by its licensing agreement to submit a report of all purchasers of the Tet-controllable expression system to TET Systems. For license information, please contact: GSF/CEO TET Systems GmbH & Co. KG, Im Neuenheimer Feld 582 69120 Heidelberg Germany Tel: +49 6221 5880400 Fax: +49 6221 5880404 email: info@tetsystems.com or use the electronic licensing request form via http://www.tetsystems.com/ip-licensing/licensing/for-profit-research
262	Vectalys Technology Vectalys’ highly concentrated and purified lentiviral vectors and its use are covered by U.S. Patent No. 13/0029379 and WO 2013/014537. The purchase price of this product includes limited, nontransferable rights to use this product solely for internal research purposes. Academic and not-for-profit research institutions whose research using the Vectalys’ Technology or the product obtained by the Vectalys’ technology when sponsored by for profit organizations, which shall receive ownership to all data and results stemming from the sponsored research, shall need a commercial license agreement from Vectalys in order to use the Vectalys’ Technology or the product obtained by the Vectalys’ technology. Please contact Vectalys for information on purchasing a license to use these products for commercial purposes: Parc Technologique du Canal, Bâtiment Canal Biotech II, 3, rue des satellites, 31400 Toulouse (France), TEL: +33(0)5 61 28 70 75, EMAIL: sandy.darrigan@vectalys.com.
264	cPPT Element cPPT Element and its use are covered by one or more patents: FR9805197 and US 60/158387 and/or other pending foreign patent applications licensed to Vectalys. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot disclose information, sell or otherwise transfer this product, its components or materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for any commercial purposes. If the buyer is not willing to accept the limitations of this limited use statement, Vectalys is willing to accept return of the product with a full refund. For information on purchasing a license to the DNA-Flap technology for purposes other than research, contact the Transfer of Technology Office, Institut Pasteur, 28 rue du Docteur Roux, 75 724 Paris Cedex 15 (www.pasteur.fr).
353	LentiFlash Technology: This product is covered by the French pending patent application FR1554381 and the PCT application PCT/FR/051152. The purchase price of this product includes limited, nontransferable rights to use this product solely for internal research purposes. Please contact Vectalys for information on purchasing a license to use these products for commercial purposes: Parc Technologique du Canal, Bâtiment Canal Biotech II, 3, rue des satellites, 31400 Toulouse (France), TEL: +33(0)5 61 28 70 75, EMAIL: sandy.darrigan@vectalys.com.

Highly concentrated and purified lentivirus for delivery of the Tet-On 3G transactivator to target cells. Any gene of interest under the control of a TRE3G promoter can be tightly controlled by the presence and absence of Dox in the culture medium. Tet-On 3G is a modified, improved Tet-On Advanced transcriptional activator protein (transactivator) which has been evolved to display far higher sensitivity to the inducer molecule dox. Tet-On 3G generates very high maximal expression and responds to lower Dox concentrations than its predecessors.

Notice to purchaser

Our products are to be used for Research Use Only. They may not be used for any other purpose, including, but not limited to, use in humans, therapeutic or diagnostic use, or commercial use of any kind. Our products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without our prior written approval.

Components

Required Products

Cat. #	Product	Size	Price	License	Quantity	Details
631101	Tet System Approved FBS, US-Sourced	500 mL	USD $902.00
Fetal Bovine Serum (FBS) that has been functionally tested for optimal use with all of our Tet Systems. This FBS does not contain trace levels of tetracycline (or derivatives) which have been observed to interfere with proper regulation of TRE-controlled gene expression. Use of this serum ensures the maximal range of induction possible with the Tet Systems. This FBS has been processed in the United States. Documents Components Image Data Back Fetal bovine serum (FBS) approved for use with tetracycline-inducible expression systems Fetal bovine serum (FBS) approved for use with tetracycline inducible expression systems. Only Takara Bio USA functionally tests FBS to be sure that no contaminating tetracycline derivatives interfere with induced expression levels. Back Our fetal bovine serum is functionally tested to guarantee consistent results with tetracycline-inducible expression systems Fetal bovine serum from Clontech is functionally tested to guarantee consistent results with tetracycline-inducible expression systems. Serum from other vendors that have not been functionally tested may contain tetracyclines that affect the maximum expression in Tet-Off systems, or generate background in Tet-On systems. Data here shows induction of luciferase expression from our CHO-AA8-Luc Tet-Off Control Cell Line using different sources of FBS. Back 631101: Tet System Approved FBS, US-Sourced

0027VCT

rLV.EF1.Tet3G-9

3 x 20 uL

USD $1938.00

License Statement

ID Number
42	Use of the Tetracycline controllable expression systems (the "Tet Technology") is covered by a series of patents including U.S. Patent # 8383364, # 9181556 , European patents EP # 1954811, #2352833 and corresponding patent claims outside these regions which are proprietary to TET Systems GmbH & Co. KG. Academic research institutions are granted an automatic license with the purchase of this product to use the Tet Technology only for internal, academic research purposes, which license specifically excludes the right to sell, or otherwise transfer, the Tet Technology or its component parts to third parties. Notwithstanding the above, academic and not-for profit research institutions whose research using the Tet Technology is sponsored by for profit organizations, which shall receive ownership to any data and results stemming from the sponsored research, shall need a commercial license agreement from TET Systems in order to use the Tet Technology. In accepting this license, all users acknowledge that the Tet Technology is experimental in nature. TET Systems GmbH & Co. KG makes no warranties, express or implied or of any kind, and hereby disclaims any warranties, representations, or guarantees of any kind as to the Tet Technology, patents, or products. All others are invited to request a license from TET Systems GmbH & Co. KG prior to purchasing these reagents or using them for any purpose. Takara Bio USA, Inc. is required by its licensing agreement to submit a report of all purchasers of the Tet-controllable expression system to TET Systems. For license information, please contact: GSF/CEO TET Systems GmbH & Co. KG, Im Neuenheimer Feld 582 69120 Heidelberg Germany Tel: +49 6221 5880400 Fax: +49 6221 5880404 email: info@tetsystems.com or use the electronic licensing request form via http://www.tetsystems.com/ip-licensing/licensing/for-profit-research
262	Vectalys Technology Vectalys’ highly concentrated and purified lentiviral vectors and its use are covered by U.S. Patent No. 13/0029379 and WO 2013/014537. The purchase price of this product includes limited, nontransferable rights to use this product solely for internal research purposes. Academic and not-for-profit research institutions whose research using the Vectalys’ Technology or the product obtained by the Vectalys’ technology when sponsored by for profit organizations, which shall receive ownership to all data and results stemming from the sponsored research, shall need a commercial license agreement from Vectalys in order to use the Vectalys’ Technology or the product obtained by the Vectalys’ technology. Please contact Vectalys for information on purchasing a license to use these products for commercial purposes: Parc Technologique du Canal, Bâtiment Canal Biotech II, 3, rue des satellites, 31400 Toulouse (France), TEL: +33(0)5 61 28 70 75, EMAIL: sandy.darrigan@vectalys.com.
264	cPPT Element cPPT Element and its use are covered by one or more patents: FR9805197 and US 60/158387 and/or other pending foreign patent applications licensed to Vectalys. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot disclose information, sell or otherwise transfer this product, its components or materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for any commercial purposes. If the buyer is not willing to accept the limitations of this limited use statement, Vectalys is willing to accept return of the product with a full refund. For information on purchasing a license to the DNA-Flap technology for purposes other than research, contact the Transfer of Technology Office, Institut Pasteur, 28 rue du Docteur Roux, 75 724 Paris Cedex 15 (www.pasteur.fr).
353	LentiFlash Technology: This product is covered by the French pending patent application FR1554381 and the PCT application PCT/FR/051152. The purchase price of this product includes limited, nontransferable rights to use this product solely for internal research purposes. Please contact Vectalys for information on purchasing a license to use these products for commercial purposes: Parc Technologique du Canal, Bâtiment Canal Biotech II, 3, rue des satellites, 31400 Toulouse (France), TEL: +33(0)5 61 28 70 75, EMAIL: sandy.darrigan@vectalys.com.

The Flash Therapeutics Inducible Reprogramming Lentiviral Vectors are prepackaged lentiviral particles expressing polycistronic Oct4, Sox2, KLF4, and Myc for reprogramming human somatic cells under the induction of doxycycline using Tet technology. These VSV-G pseudotyped viruses are capable of infecting both dividing and non-dividing cells. The high purification level of these lentiviral particles allows transduction of primary cells and immortalized cell lines without inducing any toxicity to the cells, even at high multiplicity of infection (M.O.I.). The expression of these four factors has been shown to reprogram a variety of differentiated cells into induced pluripotent stem (iPS) cells with embryonic stem (ES) cell-like properties.

Notice to purchaser

Components

Required Products

Cat. #	Product	Size	Price	License	Quantity	Details
631101	Tet System Approved FBS, US-Sourced	500 mL	USD $902.00
Fetal Bovine Serum (FBS) that has been functionally tested for optimal use with all of our Tet Systems. This FBS does not contain trace levels of tetracycline (or derivatives) which have been observed to interfere with proper regulation of TRE-controlled gene expression. Use of this serum ensures the maximal range of induction possible with the Tet Systems. This FBS has been processed in the United States. Documents Components Image Data Back Fetal bovine serum (FBS) approved for use with tetracycline-inducible expression systems Fetal bovine serum (FBS) approved for use with tetracycline inducible expression systems. Only Takara Bio USA functionally tests FBS to be sure that no contaminating tetracycline derivatives interfere with induced expression levels. Back Our fetal bovine serum is functionally tested to guarantee consistent results with tetracycline-inducible expression systems Fetal bovine serum from Clontech is functionally tested to guarantee consistent results with tetracycline-inducible expression systems. Serum from other vendors that have not been functionally tested may contain tetracyclines that affect the maximum expression in Tet-Off systems, or generate background in Tet-On systems. Data here shows induction of luciferase expression from our CHO-AA8-Luc Tet-Off Control Cell Line using different sources of FBS. Back 631101: Tet System Approved FBS, US-Sourced

Overview

What does 10⁹ TU/ml mean?
- In each microliter, there will be at least 1 x 10⁶ functional lentivirus particles.
- Each 60-µl kit is sufficient for 30 transductions (using an MOI of 10) in a 6-well plate containing 2 x 10⁵ cells/well.
Gold standard tetracycline transactivator in a ready-to-use lentivirus format.
Premium quality; produced via a multistep purification process which results in very high titers and purity.
- Functional titer provided, not a just a particle count.
- High purity—transduce target cells without cytotoxicity.
- >90% transduction efficiency can be obtained even at very low MOI.
Can be combined with any vector containing a TRE promoter to obtain tetracycline-inducible expression of your gene of interest (we recommend the TRE3G promoter).
Learn more about Tet-On 3G technology.

More Information

Applications

Tightly controlled, inducible expression of your gene of interest in hard-to-transfect mammalian cells

Additional product information

Please see the product's Certificate of Analysis for information about storage conditions, product components, and technical specifications. Please see the Kit Components List to determine kit components. Certificates of Analysis and Kit Components Lists are located under the Documents tab.

Learn more about the technology used to make our ready-to-use lentivirus particle preps

Super-pure and concentrated premade lentivirus particles

Unlike ready-to-use lentiviral particles from other suppliers, the particles in our catalog are produced via a multistep purification process that results in very high titers and high purity. High titers increase transduction efficiency, while high purity reduces cytotoxicity, allowing you to successfully transduce a large number of different cell types—including primary, immortalized, adherent, and suspension cells—while retaining high cell viability.

Technology overview Lentiviral particles FAQs

Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2022 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.

Tet-On 3G transactivator lentiviral particles

Notice to purchaser

0055VCT: rLV.EF1.Tet3G-9

Expression plasmid for inducible expression

Fetal bovine serum (FBS) approved for use with tetracycline-inducible expression systems

Our fetal bovine serum is functionally tested to guarantee consistent results with tetracycline-inducible expression systems

631101: Tet System Approved FBS, US-Sourced

Notice to purchaser

Various cell types can be transduced with Vectalys lentiviral particles, including primary and stem cell lines

Overview of the process for generating high-titer lentiviral particles

Transduction efficiency of a Vectalys GFP-expressing lentiviral vector in IMR90 cells

Comparison of the purity of lentiviruses generated with Vectalys’ method or a classic purification method

Not all titers are the same! Comparison of cells transduced with 100 M

0027VCT: rLV.EF1.Tet3G-9

Expression plasmid for inducible expression

Fetal bovine serum (FBS) approved for use with tetracycline-inducible expression systems

Our fetal bovine serum is functionally tested to guarantee consistent results with tetracycline-inducible expression systems

631101: Tet System Approved FBS, US-Sourced

Overview

More Information

Applications

Additional product information